Meeting
2023 ASCO Annual Meeting
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I).
Authors
Gopa Iyer
Memorial Sloan Kettering Cancer Center, New York, NY
Gopa Iyer , Dustin A. Deming , Michael J. Demeure , Noah Federman , Elizabeth Katherine Lee , Alexander I. Spira , David J. Kwiatkowski , Maen A. Hussein , Erlinda Maria Gordon , David G. Crockett , Kristen N. Ganjoo , Brian Schulte , Lee D. Cranmer , Li Ding , Anita N. Schmid , Willis H. Navarro , Jordi Rodon Ahnert , Meredith McKean
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Other Developmental Therapeutics
Clinical Trial Registration Number
NCT05103358
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS3168)
DOI
10.1200/JCO.2023.41.16_suppl.TPS3168
Abstract #
TPS3168
Poster Bd #
358b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
PRECISION 1: A phase 2, multicenter, open-label basket trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2.
First Author: Gopa Iyer
Poster
2024 ASCO Gastrointestinal Cancers Symposium
PRECISION 1: A phase 2, multicenter, open-label basket trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2.
First Author: Dustin A. Deming
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I).
First Author: Gopa Iyer
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I).
First Author: Dustin A. Deming